BioSpecifics Technologies Corp. (NASDAQ:BSTC) insider Thomas Wegman sold 20,000 shares of the company’s stock in a transaction on Tuesday, November 29th. The shares were sold at an average price of $48.16, for a total transaction of $963,200.00. Following the completion of the transaction, the insider now owns 964,824 shares in the company, valued at $46,465,923.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Thomas Wegman also recently made the following trade(s):

  • On Thursday, September 15th, Thomas Wegman sold 3,100 shares of BioSpecifics Technologies Corp. stock. The shares were sold at an average price of $41.21, for a total transaction of $127,751.00.
  • On Tuesday, September 13th, Thomas Wegman sold 3,605 shares of BioSpecifics Technologies Corp. stock. The shares were sold at an average price of $37.55, for a total transaction of $135,367.75.
  • On Friday, September 2nd, Thomas Wegman sold 9,201 shares of BioSpecifics Technologies Corp. stock. The shares were sold at an average price of $37.53, for a total transaction of $345,313.53.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) opened at 49.85 on Wednesday. BioSpecifics Technologies Corp. has a 12-month low of $30.70 and a 12-month high of $51.90. The firm has a market capitalization of $356.28 million, a P/E ratio of 32.80 and a beta of 1.35. The firm has a 50 day moving average of $45.99 and a 200 day moving average of $41.13.

Insider Buying and Selling by Quarter for BioSpecifics Technologies Corp. (NASDAQ:BSTC)

TRADEMARK VIOLATION NOTICE: This report was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/30/biospecifics-technologies-corp-bstc-insider-thomas-wegman-sells-20000-shares.html.

Several institutional investors have recently modified their holdings of BSTC. Morgan Stanley boosted its position in shares of BioSpecifics Technologies Corp. by 977.8% in the third quarter. Morgan Stanley now owns 2,188 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 1,985 shares in the last quarter. US Bancorp DE boosted its position in shares of BioSpecifics Technologies Corp. by 21.0% in the second quarter. US Bancorp DE now owns 3,025 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 525 shares in the last quarter. American International Group Inc. boosted its position in shares of BioSpecifics Technologies Corp. by 4.2% in the second quarter. American International Group Inc. now owns 3,110 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 126 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of BioSpecifics Technologies Corp. by 6.5% in the second quarter. Nationwide Fund Advisors now owns 3,563 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 217 shares in the last quarter. Finally, Bank of Montreal Can purchased a new position in shares of BioSpecifics Technologies Corp. during the second quarter worth about $152,000. Institutional investors own 53.71% of the company’s stock.

BSTC has been the topic of several research reports. Zacks Investment Research downgraded shares of BioSpecifics Technologies Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of BioSpecifics Technologies Corp. in a report on Thursday, October 6th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $60.00 price objective on shares of BioSpecifics Technologies Corp. in a report on Wednesday, August 10th.

BioSpecifics Technologies Corp. Company Profile

BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development.

5 Day Chart for NASDAQ:BSTC

Receive News & Stock Ratings for BioSpecifics Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp. and related stocks with our FREE daily email newsletter.